Antidepressant treatment of neuropathic pain: Looking for the mechanism

Future Neurology

Volumn 5, Issue 2, 2010, Pages 247-257

  Barrot, Michel ^a   Yalcin, Ipek ^b   Tessier, Luc Henri ^b   Freund Mercier, Marie José ^c  

^a Institut des Neurosciences Cellulaires et Intégratives UPR3212   (France)

^b CNRS   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

mimetic; Adrenoceptor; Allodynia; Antidepressant; Neuropathic pain; Neuropathy; Noradrenaline; Opioid receptor; Pain; Treatment

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOMIPRAMINE; CLONIDINE; DELTA OPIATE RECEPTOR; DESIPRAMINE; DULOXETINE; FLUOXETINE; IMIPRAMINE; MILNACIPRAN; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PLACEBO; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; XYLAZINE; YOHIMBINE;

ADJUVANT THERAPY; ALLODYNIA; ANALGESIC ACTIVITY; BINDING AFFINITY; BLURRED VISION; CHRONIC PAIN; CONSTIPATION; DELIRIUM; DEPRESSION; DIABETIC NEUROPATHY; DIZZINESS; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG WITHDRAWAL; HUMAN; LONG TERM CARE; MEMORY DISORDER; NEUROPATHIC PAIN; NEUROPATHOLOGY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMATOSENSORY DISORDER; SWEATING; TACHYCARDIA; TREATMENT DURATION; URINE RETENTION; WEIGHT GAIN; XEROSTOMIA;

EID: 77949410376     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/fnl.09.82     Document Type: Review

References (75)

1. Paoli F, Darcourt G, Cossa P: Preliminary note on the action of imipramine in painful states. Rev. Neurol. (Paris) 102, 503-504 (1960).
2. Davis JL, Lewis SB, Gerich JE, Kaplan RA, Schultz TA, Wallin JD: Peripheral diabetic neuropathy treated with amitriptyline and fuphenazine. JAMA 238, 2291-2292 (1977).
3. Attal N, Cruccu G, Haanpaa M et al.: EFNS guidelines on pharmacological treatment of neuropathic pain. Eur. J. Neurol. 13, 1153-1169 (2006).
4. Moulin DE, Clark AJ, Gilron I et al.: Pharmacological management of chronic neuropathic pain-consensus statement and guidelines from the Canadian Pain Society. Pain Res. Manag. 12, 13-21 (2007).
5. Loeser JD, Treede RD: The Kyoto Protocol of IASP Basic Pain Terminology. Pain 137, 473-477 (2008).
6. Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Toubol C: Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 136, 380-387 (2008).
7. Attal N, Fermanian C, Fermanian J, Lanteri-Minet M, Alchaar H, Bouhassira D: Neuropathic pain: are there distinct subtypes depending on the aetiology or anatomical lesion? Pain 138, 343-353 (2008).
8. Nicholson B, Verma S: Comorbidities in chronic neuropathic pain. Pain Med. 5, 9-27 (2004).
9. O'Connor AB: Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy. Pharmacoeconomics 27, 95-112 (2009).
10. Saarto T, Wiffen PJ: Antidepressants for neuropathic pain. Cochrane Database Syst. Rev. 4, CD005454 (2007).
11. Briley M: Clinical experience with dual action antidepressants in different chronic pain syndromes. Hum. Psychopharmacol. 1, 21-25 (2004).
12. Quilici S, Chancellor J, Löthgren M et al.: Meta-ana lysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurology 9, 6 (2009).
13. Max MB, Culnane M, Schafer SC et al.: Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 37, 589-596 (1987).
14. Fishbain DA, Detke MJ, Wernicke J, Chappell AS, Kajdasz DK: The relationship between antidepressant and analgesic responses: fndings from six placebo-controlled trials assessing the effcacy of duloxetine in patients with major depressive disorder. Curr. Med. Res. Opin. 24, 3105-3115 (2008).
15. Max MB, Lynch SA, Mir J, Shoaf SE, Smoller B, Dubner R: Effects of desipramine, amitriptyline, and fuoxetine on pain in diabetic neuropathy. N. Engl. J. Med. 326, 1250-1256 (1992).
16. Richeimer SH, Bajwa ZH, Kahraman SS, Ransil BJ, Warfeld CA: Utilization patterns of tricyclic antidepressants in a multidisciplinary pain clinic: a survey. Clin. J. Pain 13, 324-329 (1997).
17. Kajdasz DK, Iyengar S, Desaiah D et al.: Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based fndings from post hoc ana lysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. Clin. Ther. 29, 2536-2546 (2007).
18. Sultan A, Gaskell H, Derry S, Moore RA: Duloxetine for painful diabetic neuropathy and fbromyalgia pain: systemic review of randomized trials. BMC Neurology 8, 29 (2008).
19. Lee RL, Spencer PS: Effect of tricyclic antidepressants on analgesia activity in laboratory animals. Postgrad. Med. J. 56, 19-24 (1980).
20. Testa R, Angelico P, Abbiati GA: Effect of citalopram, amineptine, imipramine and nortriptyline on stress-induced (footshock) analgesia in rats. Pain 29, 247-255 (1987).
21. Bomholt SF, Mikkelsen JD, Blackburn-Munro G: Antinociceptive effects of antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain. Neuropharmacology 48, 252-263 (2005).
22. Benbouzid M, Choucair-Jaafar N, Yalcin I et al.: Chronic, but not acute, tricyclic antidepressant treatment alleviates neuropathic allodynia after sciatic nerve cuffng in mice. Eur. J. Pain 12, 1008-1017 (2008).
23. Jett MF, McGuirk J, Waligora D, Hunter JC: The effects of mexiletine, desipramine and fuoxetine in rat models involving central sensitization. Pain 69, 161-169 (1997).
24. Idänpään-Heikkilä JJ, Guilbaud G: Pharmacological studies on a rat model of trigeminal neuropathic pain: baclofen, but not carbamazepine, morphine or tricyclic antidepressants, attenuate the allodynia-like behaviour. Pain 79, 281-290 (1999).
25. Esser MJ, Sawynok J: Acute amitriptyline in a rat model of neuropathic pain: differential symptom and route effects. Pain 80, 643-653 (1999).
26. Takasaki I, Andoh T, Nitta M et al.: Pharmacological and immunohistochemical characterization of a mouse model of acute herpetic pain. Jpn. J. Pharmacol. 83, 319-326 (2000).
27. Rodrigues-Filho R, Campos MM, Ferreira J, Santos AR, Bertelli JA, Calixto JB: Pharmacological characterization of the rat brachial plexus avulsion model of neuropathic pain. Brain Res. 1018, 159-170 (2004).
28. Walczak JS, Pichette V, Leblond F, Desbiens K, Beaulieu P: Behavioral, pharmacological and molecular characterization of the saphenous nerve partial ligation: a new model of neuropathic pain. Neuroscience 132, 1093-1102 (2004).
29. Rode F, Broløs T, Blackburn-Munro G, Bjerrum OJ: Venlafaxine compromises the antinociceptive actions of gabapentin in rat models of neuropathic and persistent pain. Psychopharmacology 187, 364-375 (2006).
30. 2-adrenoceptors are essential for desipramine, venlafaxine or reboxetine action in neuropathic pain. Neurobiol. Dis. 33, 386-394 (2009).
31. Hota D, Bansal V, Pattanaik S: Evaluation of ketamine, nimodipine, gabapentin and imipramine in partial sciatic nerve transaction model of neuropathic pain in rat: an experimental study. Meth. Find Clin. Pharmacol. 29, 443-446 (2007).
32. Matsuzawa-Yanagida K, Narita M, Nakajima M et al.: Usefulness of antidepressants for improving the neuropathic pain-like state and pain-induced anxiety through actions at different brain sites. Neuropsychopharmacology 33, 1952-1965 (2008).
33. Jones KL, Finn DP, Governo RJM et al.: Identifcation of discrete sites of action of chronic treatment with desipramine in a model of neuropathic pain. Neuropharmacology 56, 405-413 (2009).
34. Takeda R, Watanabe Y, Ikeda T et al.: Analgesic effect of milnacipran is associated with c-Fos expression in the anterior cingulate cortex in the rat neuropathic pain model. Neurosci. Res. 64, 380-384 (2009).
35. Micó JA, Ardid D, Berrocoso E, Eschalier A: Antidepressants and pain. Trends Pharmacol. Sci. 27, 348-354 (2006).
36. Coyle JT, Duman RS: Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 38, 157-160 (2003).
37. Duman RS: Pathophysiology of depression: the concept of synaptic plasticity. Eur. Psychiatry 17, 306-310 (2002).
38. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM: Neurobiology of depression. Neuron 34, 13-25 (2002).
39. Tsankova N, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ: Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat. Neurosci. 9, 519-525 (2006).
40. Tsankova N, Renthal W, Kumar A, Nestler EJ: Epigenetic regulation in psychiatric disorders. Nat. Rev. Neurosci. 8, 355-367 (2007).
41. Wallace DL, Huan MH, Graham DL et al.: CREB regulation of nucleus accumbens excitability mediates social isolation-induced behavioral defcits. Nat. Neurosci. 12, 200-209 (2009).
42. + currents in rat sensory neurons. Anesthesiology 94, 137-144 (2001).
43. Dick IE, Brochu RM, Purohit Y, Kaczorowski GJ, Martin WJ, Priest BT: Sodium channel blockade may contribute to the analgesic effcacy of antidepressants. J. Pain 8, 315-324 (2007).
44. Punke MA, Friederich P: Amitriptyline is a potent blocker of human Kv1.1 and Kv7.2/7.3 channels. Anesth. Analg. 104, 1256-1264 (2007).
45. Eisenach JC, Gebhart GF: Intrathecal amitriptyline acts as an N-methyl-D-aspartate receptor antagonist in the presence of infammatory hyperalgesia in rats. Anesthesiology 83, 1046-1054 (1995).
46. Estebe JP, Myers RR: Amitriptyline neurotoxicity: dose-related pathology after topical application to rat sciatic nerve. Anesthesiology 100, 1519-1525 (2004).
47. Fukushima FB, Barros GA, Marques ME, Vidal EI, Ganem EM: The neuraxial effects of intraspinal amitriptyline at low concentrations. Anesth. Analg. 109, 965-971 (2009).
48. von Kügelgen I, Allgaier C, Schobert A, Starke K: Co-release of noradrenaline and ATP from cultured sympathetic neurons. Neuroscience 61, 199-202 (1994).
49. Guieu R, Peragut JC, Roussel P et al.: Adenosine and neuropathic pain. Pain 68, 271-274 (1996).
50. Guieu R, Sampiéri F, Pouget J, Guy B, Rochat H: Adenosine in painful legs and moving toes syndrome. Clin. Pharmacol. 17, 460-469 (1994).
51. Esser MJ, Chase T, Allen GV, Sawynok J: Chronic administration of amitriptyline and caffeine in a rat model of neuropathic pain: multiple interactions. Eur. J. Pharmacol. 430, 211-218 (2001).
52. Ulugol A, Karadag HC, Tamer M, Firat Z, Aslantas A, Dokmeci I: Involvement of adenosine in the anti-allodynic effect of amitriptyline in streptozotocin-induced diabetic rats. Neurosci. Lett. 328, 129-132 (2002).
53. Sawynok J, Reid AR, Fredholm BB: Caffeine reverses antinociception by amitriptyline in wild-type mice but not in those lacking adenosine A1 receptors. Neurosci. Lett. 440, 181-184 (2008).
54. Benbouzid M, Pallage V, Rajalu M et al.: Sciatic nerve cuffng in mice: a model of sustained neuropathic pain. Eur. J. Pain 12, 591-599 (2008).
55. 2- adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann. Neurol. 65, 218-225 (2009).
56. Barrot M, Yalcin I, Choucair-Jaafar N, Benbouzid M, Freund-Mercier MJ: From antidepressant drugs to b-mimetics: preclinical insights on potential new treatments for neuropathic pain. Recent Pat. CNS Drug Discov. 4, 182-189 (2009).
57. Choucair-Jaafar N, Yalcin I, Rodeau JL, Waltisperger E, Freund-Mercier MJ, Barrot M: b2-adrenoceptor agonists alleviate neuropathic allodynia in mice after chronic treatment. Brit. J. Pharmacol. 158, 1683-1694 (2009).
58. Yalcin I, Tessier LH, Petit-Demoulière N et al.: Chronic treatment with agonists of b2-adrenergic receptors in neuropathic pain. Exp. Neurol. 221, 115-121 (2010).
59. Reichenberg K, Gaillard-Plaza G, Montastruc JL: Infuence of naloxone on the antinociceptive effects of some antidepressant drugs. Arch. Int. Pharmacodyn. Ther. 275, 78-85 (1985).
60. Valverde O, Mico JA, Maldonado R, Mellado M, Gibert-Rahola J: Participation of opioid and monoaminergic mechanisms on the antinociceptive effect induced by tricyclic antidepressants in two behavioural pain tests in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 18, 1073-1092 (1994).
61. Gray AM, Spencer PS, Sewell RD: The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds. Brit. J. Pharmacol. 124, 669-674 (1998).
62. Su X, Gebhart GF: Effects of tricyclic antidepressants on mechanosensitive pelvic nerve afferent fbers innervating the rat colon. Pain 76, 105-114 (1998).
63. Schreiber S, Backer MM, Pick CG: The antinociceptive effect of venlafaxine in mice is mediated through opioid and adrenergic mechanisms. Neurosci. Lett. 273, 85-88 (1999).
64. Schreiber S, Bleich A, Pick CG: Venlafaxine and mirtazapine: different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects-a possible opioid involvement in severe depression? J. Mol. Neurosci. 18, 143-149 (2002).
65. Marchand F, Ardid D, Chapuy E, Alloui A, Jourdan D, Eschalier A: Evidence for an involvement of supraspinal d-and spinal m-opioid receptors in the antihyperalgesic effect of chronically administered clomipramine in mononeuropathic rats. J. Pharmacol. Exp. Ther. 307, 268-274 (2003).
66. Ortega-Alvaro A, Acebes I, Saracibar G, Echevarria E, Casis L, Mico JA: Effect of the antidepressant nefazodone on the density of cells expressing m-opioid receptors in discrete brain areas processing sensory and affective dimensions of pain. Psychopharmacology 176, 305-311 (2004).
67. Benbouzid M, Gaveriaux-Ruff C, Yalcin I et al.: d-opioid receptors are critical for tricyclic antidepressant treatment of neuropathic allodynia. Biol. Psychiatry 63, 633-636 (2008).
68. Bohren Y, Karavelic D, Tessier LH et al.: m-opioid receptors are not necessary for nortriptyline treatment of neuropathic allodynia. DOI: 10.1016/j.ejpain.2009.11.014 Eur. J. Pain (2010) (In press).
69. Pick CG, Paul D, Eison MS, Pasternak GW: Potentiation of opioid analgesia by the antidepressant nefazodone. Eur. J. Pharmacol. 211, 375-381 (1992).
70. Fuchs PN, Lariviere WR, Balinsky M, Melzack R: Acute amitriptyline treatment produces non-opioid-mediated analgesia in the formalin and bee venom tests. Pathophysiology 3, 227-231 (1996).
71. Ghelardini C, Galeotti N, Bartolini A: Antinociception induced by amitriptyline and imipramine is mediated by a2A-adrenoceptors. Jpn. J. Pharmacol. 82, 130-137 (2000).
72. Marchand F, Alloui A, Chapuy E et al.: Evidence for a monoamine mediated, opioid-independent, antihyperalgesic effect of venlafaxine, a non-tricyclic antidepressant, in a neurogenic pain model in rats. Pain 103, 229-235 (2003).
73. Marchand F, Alloui A, Chapuy E et al.: The antihyperalgesic effect of venlafaxine in diabetic rats does not involve the opioid system. Neurosci. Lett. 342, 105-108 (2003).
74. Attal N, Fermanian C, Fermanian J, Lanteri-Minet M, Alchaar H, Bouhassira D: Neuropathic pain: are there distinct subtypes depending on the aetiology or anatomical lesion? Pain 138, 434-1353 (2008).
75. Hansson PT, Attal N, Baron R, Cruccu G: Toward a defnition of pharmacoresistant neuropathic pain. Eur. J. Pain 13, 439-440 (2009).